Physiomics Awarded New Contract by Numab Therapeutics
Why we think this is good
The RNS announcement highlights a new contract award for Physiomics, which extends the company's long-standing collaboration with Numab Therapeutics. This is a positive development, as it reinforces Physiomics' role as a trusted partner providing specialist modelling support to inform critical stages of drug development. The contract is expected to be completed within the next two months, indicating a relatively short timeline. While the contract value is not disclosed, the RNS notes this is an extension of an existing relationship, suggesting the contract is likely significant for the company. Overall, the news is viewed positively, but does not meet the criteria for a 'Very Good' rating as it does not represent a transformational event or an explicit profit upgrade.
Key Points
- Physiomics awarded new contract by Numab Therapeutics
- Project will involve modelling and simulation to support pre-clinical development of a cancer treatment
- Contract is an extension of the companies' long-standing collaboration
Summary
Physiomics plc, a leading mathematical modelling, data science and biostatistics company, has been awarded a new contract by its long-standing client, Numab Therapeutics AG. The project will involve the application of modelling and simulation techniques to inform pre-clinical development of a multi-specific antibody designed to activate anti-tumor immune responses for the treatment of cancer. This latest collaboration extends the history of the Company working with Numab Therapeutics in applying Model Informed Drug Development to address complex challenges with mathematical modelling and simulation techniques.